|Articles|February 26, 2013
Information about ACC.13
News and updates about ACC.13, the 2013 Scientific Session of the American College of Cardiology.
Advertisement
ACC.13 — Discovery to Delivery
March 9-11, 2013
San Francisco, CA
HCPLive will be providing up-to-date coverage of key sessions and news from ACC.13. In the meantime, we’ve compiled some important links and information about the conference for attendees.
Clinical Education
ACC.13 sessions are organized into 16 learning pathways:
Cutting-edge Research
ACC.13 will feature five
ACC.13 Opening Showcase and Late-Breaking Clinical Trials
Session 300
Saturday, March 9, 8 — 10:10am
South, Esplanade Ballroom
Late-Breaking Clinical Trials II: Interventional
Session 301
Sunday, March 10, 8 — 9:30am
South, Esplanade Ballroom
Late-Breaking Clinical Trials III: Chronic CAD/Stable Ischemic Heart Disease and Acute Coronary Syndromes
Session 302
Sunday, March 10, 10:45am — 12:15pm
South, Esplanade Ballroom
Late-Breaking Clinical Trials IV: General Cardiology
Session 303
Monday, March 11, 8 — 9:30am
South, Esplanade Ballroom
Late-Breaking Clinical Trials V: Heart Failure
Session 304
Monday, March 11, 10:45am — 12:15pm
South, Esplanade Ballroom
ACC.13 Exhibit Hall
At the ACC.13 Expo, “more than 300 companies and organizations will showcase the latest advances in pharmaceuticals, imaging, devices, health IT and the services you need to provide high-quality care to your patients.”
Expo Hall hours
Saturday, March 9: 9:30am — 4:45pm
Sunday, March 10: 9:30am — 4:45pm
Monday, March 11: 9:30am — 2:00pm
View an interactive ACC.13 Expo floor plan
ACC.13 Planning
The ACC has created several tools to allow attendees to customize their conference experience. The
You can also browse the session schedule in PDF format, organized by day or learning pathway. Each PDF includes full session, presentation and speaker information.
Daily schedules:
Schedules by learning pathway:
TCT@ACC-i2: Invasive and Interventional Cardiology
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
TRIUMPH-1: Retatrutide Substantially Lowers Weight, BMI in Patients With Obesity or Overweight
2
TRANSCEND-T2D-1: Retatrutide Demonstrates Superior Weight Loss and A1c Results Versus Placebo
3
Machine Learning Model Predicts Type 2 Diabetes Risk Up To 10 Years Out
4
High-Dose Semaglutide Preserves Kidney Function, Reduces Inflammation in Obesity Without Diabetes
5